Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Diabetes|March 20, 2010
Extracellular fatty acid synthase: a possible surrogate biomarker of insulin resistanceJose Manuel Fernandez-Real, Javier A Menendez, Jose Maria Moreno-Navarrete, et al.
Cell Cycle (Georgetown, Tex.)|February 24, 2012
Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205Sílvia Cufí, Alejandro Vazquez-Martin, Cristina Oliveras-Ferraros, et al.
Oncology Reports|March 20, 2012
Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatmentCristina Oliveras-Ferraros, Anna Massaguer Vall-Llovera, Alejandro Vazquez-Martin, et al.
Cell Cycle (Georgetown, Tex.)|August 27, 2013
Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathwayBruna Corominas-Faja, Sílvia Cufí, Cristina Oliveras-Ferraros, et al.
Scientific Reports|September 3, 2013
IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutationsAlejandro Vazquez-Martin, Sílvia Cufí, Cristina Oliveras-Ferraros, et al.
Scientific Reports|August 22, 2013
Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivoSílvia Cufí, Rosa Bonavia, Alejandro Vazquez-Martin, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|August 7, 2013
Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cellsSílvia Cufí, Rosa Bonavia, Alejandro Vazquez-Martin, et al.
International Journal of Oncology|August 12, 2011
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line modelsCristina Oliveras-Ferraros, Alejandro Vazquez-Martin, Bernardo Queralt, et al.
Mediators of Inflammation|January 24, 2014
Ubiquitous transgenic overexpression of C-C chemokine ligand 2: a model to assess the combined effect of high energy intake and continuous low-grade inflammationEsther Rodríguez-Gallego, Marta Riera-Borrull, Anna Hernández-Aguilera, et al.
Cell Cycle (Georgetown, Tex.)|February 2, 2013
Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agentsJavier A Menendez, Jorge Joven, Gerard Aragonès, et al.
Pageof 8